VISION 2010
By 2010, the Society will be a fully international, educational and
scientific organization that fosters excellence in the core disciplines
of pharmacoeconomics/health economics and outcomes research and the use
of this research information in health care decisions.
To achieve this vision, the Society will have:
- Supported the growth of regional (e.g., Europe, Asia, U.S.,
South America) ISPOR groups under an organizational structure that
fosters the development and application of core disciplines while
encouraging local priorities and practices to guide practical
translation and implementation.
- Enhanced its reputation by fostering and recognizing excellence
in our core disciplines, while maintaining its strength as a
marketplace of ideas and opportunities for its members.
- Expanded its purview to include all individuals interested in
the production and/or use of information on the costs and
consequences of health care interventions as well as the processes
by which health care decisions are made.
- Actively recruited as members persons focused on biotechnology
products, biologics, medical devices, and genomic applications.
- Actively reached out to decision makers, enhancing their use of
outcomes research and enhancing membership understanding of the
basis of real-world decision-making
In addition, ISPOR shall continue to support its core activities and
commitments including: annual US, European, and Asian meetings;
Value in Health and other
publications; educational activities; fostering student participation
and development; and serving as a marketplace for networking. [ISPOR
Vision 2010 Committee]
VISION 2010 IMPLEMENTATION
To implement a plan to realize this ISPOR Vision, the following five key areas were identified and activities in each key area were proposed by the Vision 2010 Implementation Task Force. The actions taken by the Board of Directors for each proposed activity follow.
ISPOR Vision 2010
Task Force:
Co-chairs: Marc Berger MD, Merck & Company, Inc.,
West Point, PA, USA and Gerry Oster PhD, PAI, Brookline, MA, USA;
Members: Ron Akehurst BSc, The University of Sheffield, Sheffield,
UK; Jon Clouse RPh, MS, United Health Care, Brevard, NC; Isao Kamae
MD, DrPH, Kobe University, Kobe, Japan; Bryan Luce PhD, MBA, United
BioSource Corporation, Bethesda, MD, USA; Karen Rascati PhD, RPh,
University of Texas, Austin, TX, USA
ISPOR Vision 2010 Implementation Task Force:
Co-chairs: Lieven
Annemans PhD, MSc, Ghent University, Brussels, Belgium and Isao
Kamae MD, DrPH, Kobe University, Kobe, Japan;
Members: Shu Chuen Li
PhD, MBA, MSc, BSc, National University of Singapore, Singapore,
Singapore; Arne Heissel PhD, Amgen Europe, Zug, Switzerland; Adrian
Levy PhD, Oxford Outcomes, Vancouver, BC, Canada; Joseph DiCesare
RPh, MPH, Novartis Pharmaceuticals Corp., Hanover, NJ, USA; Gerry
Oster PhD, PAI, Brookline, MA, USA; Nancy Klein Leidy PhD, UBC
Health Care Analytics Group, Bethesda, MD, USA
ISPOR Board of Directors 2006-2007
President:Michael Drummond PhD, Professor of Health Economics, University of York, Heslington, York, UK; President-Elect: Diana Brixner PhD, Associate Professor and Chair, University of Utah, Salt Lake City, UT, USA; Past President: Peter J. Neumann, ScD, Professor, Tufts University School of Medicine, Boston, MA, USA; Director (2006-2008) Marc Berger MD, Vice President, Outcomes Research & Management, Merck & Company, Inc., West Point, PA, USA;
Director (2005-2007): Joyce Cramer, Associate Research Scientist, Yale University School of Medicine, West Haven, CT, USA;
Director (2006-2008) Shu Chuen Li PhD, Associate Professor, National University of Singapore, Singapore, Singapore;
Director ( 2006-2008) Uwe Siebert MD, ScD, Professor of Public Health, University of Health Sciences, Medical Hall, Austria;
Director (2005-2007)Scott Ramsey MD, PhD, Full Member, Professor, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Treasurer (2004-2007) Lorne Basskin PharmD, Pharmacy Director, HealthSouth Sunrise Rehabilitation Hospital, Cooper City, FL, USA
|
